Ho Thao T, Nguyen Jasmine T, Liu Juping, Stanczak Pawel, Thompson Aaron A, Yan Yingzhuo G, Chen Jasmine, Allerston Charles K, Dillard Charles L, Xu Hao, Shoger Nicholas J, Cameron Jill S, Massari Mark E, Aertgeerts Kathleen
Department of Structural Biology, Dart Neuroscience, 12278 Scripps Summit Drive, San Diego, CA 92131, USA.
Department of Preclinical Development, Dart Neuroscience, 12278 Scripps Summit Drive, San Diego, CA 92131, USA.
Protein Expr Purif. 2017 May;133:41-49. doi: 10.1016/j.pep.2017.03.002. Epub 2017 Mar 3.
Recent innovative approaches to stabilize and crystallize GPCRs have resulted in an unprecedented breakthrough in GPCR crystal structures as well as application of the purified receptor protein in biophysical and biochemical ligand binding assays. However, the protein optimization process to enable these technologies is lengthy and requires iterative overexpression, solubilization, purification and functional analysis of tens to hundreds of protein variants. Here, we report a new and versatile method to screen in parallel hundreds of GPCR variants in HEK293 produced virus-like particles (VLPs) for protein yield, stability, functionality and ligand binding. This approach reduces the time and resources during GPCR construct optimization by eliminating lengthy protein solubilization and purification steps and by its adaptability to many binding assay formats (label or label-free detection). We exemplified the robustness of our VLP method by screening 210 GALR3-VLP variants in a radiometric agonist-based binding assay and a subset of 88 variants in a label-free antagonist-based assay. The resulting GALR3 agonist or antagonist stabilizing variants were then further used for recombinant protein expression in transfected insect cells. The final purified protein variants were successfully immobilized on a biosensor chip and used in a surface plasmon resonance binding assay.
近期用于稳定和结晶G蛋白偶联受体(GPCR)的创新方法,在GPCR晶体结构方面取得了前所未有的突破,同时也将纯化的受体蛋白应用于生物物理和生化配体结合试验中。然而,实现这些技术的蛋白质优化过程冗长,需要对数十至数百种蛋白质变体进行反复的过表达、溶解、纯化和功能分析。在此,我们报告了一种新的通用方法,可在HEK293细胞产生的病毒样颗粒(VLP)中并行筛选数百种GPCR变体,以检测蛋白质产量、稳定性、功能和配体结合情况。这种方法通过省去冗长的蛋白质溶解和纯化步骤,并因其对多种结合试验形式(标记或无标记检测)的适应性,减少了GPCR构建体优化过程中的时间和资源。我们通过在基于放射性激动剂的结合试验中筛选210种GALR3-VLP变体,并在基于无标记拮抗剂的试验中筛选88种变体的子集,例证了我们VLP方法的稳健性。然后,将所得的GALR3激动剂或拮抗剂稳定变体进一步用于转染昆虫细胞中的重组蛋白表达。最终纯化的蛋白质变体成功固定在生物传感器芯片上,并用于表面等离子体共振结合试验。